Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;46(3):451-461.
doi: 10.1111/ced.14482. Epub 2020 Nov 9.

Skin manifestations of COVID-19 in children: Part 2

Affiliations
Review

Skin manifestations of COVID-19 in children: Part 2

D Andina et al. Clin Exp Dermatol. 2021 Apr.

Abstract

The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults, as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discussed one of the first and most widespread cutaneous manifestations of COVID-19, chilblain-like lesions. In this part of the review, we describe other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome. In Part 3, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children for both COVID-19 and any other pre-existing conditions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a,b) Typical targetand targetoid lesions in COVID‐19‐related erythema multiforme.
Figure 2
Figure 2
Urticaria in a child with COVID‐19.
Figure 3
Figure 3
Vesicular exanthem of COVID‐19.
Figure 4
Figure 4
(a,b) Erythmatous exanthem in paediatric inflammatory multisystem syndrome.
Figure 5
Figure 5
Purpuric rash in a child with suspected COVID‐19.
Figure 6
Figure 6
Maculopapular exanthemin COVID‐19.
Figure 7
Figure 7
(a,b) Pityriasis rosea‐like eruption intwo childrenwith suspected COVID‐19.

Comment in

References

    1. Grünwald P, Mockenhaupt M, Panzer R, Emmert S. Erythema multiforme, Stevens‐Johnson syndrome/toxic epidermal necrolysis – diagnosis and treatment. J Dtsch Dermatol Ges 2020; 18: 547–53. - PubMed
    1. French LE, Prins C. Erythema multiforme, Stevens‐Johnson syndrome and toxic epidermal necrolysis. In: Dermatology, 3rd edn (Bolognia JL, Jorizzo JL, Schaffer JV, ed). Atlanta: Elsevier Saunders, 2012; 319–33.
    1. Siedner‐Weintraub Y, Gross I, David A et al. Paediatric erythema multiforme: epidemiological, clinical and laboratory characteristics. Acta Derm Venereol 2017; 97: 489–92. - PubMed
    1. Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol 2012; 51: 889–902. - PubMed
    1. Galván Casas C, Català A, Carretero Hernández G et al. Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183: 71–7. - PMC - PubMed